

### Remarks

Support for the addition of New Claims 30 through 65 may be found generally through out the specification; specifically, on pages 14-30 and pages 77-91; and more specifically, in the following corresponding locations in the specification.

Claims 30 and 48 - pg 77, line 16-19

Claims 31 and 49 - pg 19, lines 6-9

Claims 32 and 50 - pg 78, lines 25-28

Claims 33 and 51 - pg 16, lines 6-7

Claims 34 and 52 - pg 16, lines 6-7

Claims 35 and 53 - pg 19, lines 14-25

Claims 36 and 54 - pg 16, line 8; and pg 20, line 5

Claims 37 and 55 - pg 19, line 33 - pg 20, lines 6-2; and pg 78, lines 5-10

Claims 38 and 56 - pg 18, lines 3-16


Claims 39-46 and 57-64 - pg 29, lines 1-6

Claims 47 and 65 - pg 26, line 18 - pg 28, line 34

Claims 1-29 have been cancelled without waiver or prejudice and without admitting anticipation or obviousness. The subject matter has been limited to the use of neutral endopeptidase inhibitors in response to a second restriction requirement within the Group I election in the pending parent application. Applicants reserve the right to claim non-elected subject matter included in the cancelled claims in subsequent divisional applications.

Respectfully Submitted By:

October 15, 2003



Arlene K. Musser

Registration No. 37,895

Pfizer Inc.  
Patent Department, MS: 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0871